Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2020

Open Access 01-08-2020 | Solid Tumor | Review

Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance

Authors: Łukasz Zadka, Damian J. Grybowski, Piotr Dzięgiel

Published in: Cellular Oncology | Issue 4/2020

Login to get access

Abstract

Background

Tumor initiation and subsequent progression are usually long-term processes, spread over time and conditioned by diverse aspects. Many cancers develop on the basis of chronic inflammation; however, despite dozens of years of research, little is known about the factors triggering neoplastic transformation under these conditions. Molecular characterization of both pathogenetic states, i.e., similarities and differences between chronic inflammation and cancer, is also poorly defined. The secretory activity of tumor cells may change the immunophenotype of immune cells and modify the extracellular microenvironment, which allows the bypass of host defense mechanisms and seems to have diagnostic and prognostic value. The phenomenon of immunosuppression is also present during chronic inflammation, and the development of cancer, due to its duration, predisposes patients to the promotion of chronic inflammation. The aim of our work was to discuss the above issues based on the latest scientific insights. A theoretical mechanism of cancer immunosuppression is also proposed.

Conclusions

Development of solid tumors may occur both during acute and chronic phases of inflammation. Differences in the regulation of immune responses between precancerous states and the cancers resulting from them emphasize the importance of immunosuppressive factors in oncogenesis. Cancer cells may, through their secretory activity and extracellular transport mechanisms, enhance deterioration of the immune system which, in turn, may have prognostic implications.
Literature
1.
K. T. Schultz, F. Grieder, Structure and function of the immune system. Toxicol. Pathol. 15, 262–264 (1987)
2.
L. V. Parijs, Homeostasis and self-tolerance in the immune ssystem: Turning lymphocytes off. Science 280, 243–248 (1998)
3.
M. Bradshaw, J. Linnoila, An overview of autoimmune and paraneoplastic encephalitides. Semin. Neurol. 38, 330–343 (2018)
4.
J. Wu, X. Xu, E. J. Lee, A. Y. Shull, L. Pei, F. Awan, X. Wang, J. H. Choi, L. Deng, H. B. Xin, W. Zhong, J. Liang, Y. Miao, Y. Wu, L. Fan, J. Li, W. Xu, H. Shi, Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming. Oncotarget 7, 40558–40570 (2016)
5.
V. Friman, O. Winqvist, C. Blimark, P. Langerbeins, H. Chapel, F. Dhalla, Secondary immunodeficiency in lymphoproliferative malignancies. Hematol. Oncol. 34, 121–132 (2016)
6.
C. Gudiol, J. M. Aguado, J. Carratalà, Bloodstream infections in patients with solid tumors. Virulence 7, 298–308 (2016)
7.
N. De Silva, J. Jackson, C. Steer, Infections, resistance patterns and antibiotic use in patients at a regional cancer centre. Intern Med. J. 48, 323–329 (2018)
8.
C. Goertzen, H. Mahdi, C. Laliberte, T. Meirson, D. Eymael, H. Gil-Henn, M. Magalhaes, Oral inflammation promotes oral squamous cell carcinoma invasion. Oncotarget 9, 29047-29063 (2018)
9.
A. Lasfar, A. Zloza, A. W. Silk, L. Y. Lee, K. A. Cohen-Solal, Interferon Lambda: Toward a Dual Role in Cancer. J. Interf. Cytokine Res. 39, 22–29 (2019)
10.
E. Berger, C. Delpierre, F. S. Hosnijeh, M. Kelly-Irving, L. Portengen, I. A. Bergdahl, A. S. Johansson, V. Krogh, D. Palli, S. Panico, C. Sacerdote, R. Tumino, S. A. Kyrtopoulos, P. Vineis, M. Chadeau-Hyam, R. Vermeulen, R. Castagné, Association between low-grade inflammation and Breast cancer and B-cell Myeloma and Non-Hodgkin Lymphoma: findings from two prospective cohorts. Sci. Rep. 8, 10805 (2018)
11.
K. J. Gauger, L. M. Bassa, E. M. Henchey, J. Wyman, J. Ser-Dolansky, A. Shimono, S. S. Schneider, The effects of diet induced obesity on breast cancer associated pathways in mice deficient in SFRP1. Mol. Cancer 13, 117 (2014)
12.
N. Shivappa, C. Niclis, J. B. Coquet, M. D. Román, J. R. Hébert, M. Del P. Diaz, Increased inflammatory potential of diet is associated with increased odds of prostate cancer in Argentinian men. Cancer Causes Control 29, 803–813 (2018)
13.
L. Huang, S. Liu, Y. Lei, K. Wang, M. Xu, Y. Chen, B. Liu, Y. Chen, Q. Fu, P. Zhang, K. Qin, Y. Cai, S. Fu, S. Ge, X. Yuan, Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection. Oncotarget 7, 44185-44193 (2016)
14.
L. Zheng, K. Zou, C. Yang, F. Chen, T. Guo, B. Xiong, Inflammation-based indexes and clinicopathologic features are strong predictive values of preoperative circulating tumor cell detection in gastric cancer patients. Clin. Transl. Oncol. 19, 1125–1132 (2017)
15.
B. Mlecnik, G. Bindea, H. K. Angell, P. Maby, M. Angelova, D. Tougeron, S. E. Church, L. Lafontaine, M. Fischer, T. Fredriksen, M. Sasso, A. M. Bilocq, A. Kirilovsky, A. C. Obenauf, M. Hamieh, A. Berger, P. Bruneval, J. J. Tuech, J. C. Sabourin, F. Le Pessot, J. Mauillon, A. Rafii, P. Laurent-Puig, M. R. Speicher, Z. Trajanoski, P. Michel, R. Sesboüe, T. Frebourg, F. Pagès, V. Valge-Archer, J. B. Latouche, J. Galon, Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44, 698–711 (2016)
16.
G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, R. D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002)
17.
D. S. Chen, I. Mellman, Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1–10 (2013)
18.
D. Satgé, A tumor profile in primary immune deficiencies challenges the cancer immune surveillance concept. Front Immunol. 9, 1149 (2018)
19.
A. M. Westbrook, A. Szakmary, R. H. Schiestl, Mechanisms of intestinal inflammation and development of associated cancers: Lessons learned from mouse models. Mutat. Res. 705, 40–59 (2010)
20.
A. Bektas, S. H. Schurman, R. Sen, L. Ferrucci, Human T cell immunosenescence and inflammation in aging. J. Leukoc. Biol. 102, 977–988 (2017)
21.
A. M. Minihane, S. Vinoy, W. R. Russell, A. Baka, H. M. Roche, K. M. Tuohy, J. L. Teeling, E. E. Blaak, M. Fenech, D. Vauzour, H. J. McArdle, B. H. A. Kremer, L. Sterkman, K. Vafeiadou, M. M. Benedetti, C. M. Williams, P. C. Calder, Low-grade inflammation, diet composition and health: current research evidence and its translation. Br. J. Nutr. 114, 999–1012 (2015)
22.
D. Janevska, V. Chaloska-Ivanova, V. Janevski, Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced. J. Med. Sci. 3, 732–736 (2015)
23.
G. A. Decker, M. J. Batheja, J. M. Collins, A. C. Silva, K. L. Mekeel, A. A. Moss, C. C. Nguyen, D. F. Lake, L. J. Miller, Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol. 6, 246–54 (2010)
24.
F. Haggar, R. Boushey, Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin. Colon. Rectal. Surg. 22, 191–197 (2009)
25.
C. Bosetti, F. Turati, C. La Vecchia, Hepatocellular carcinoma epidemiology. Best Pract. Res. Clin. Gastroenterol. 28, 753–770 (2014)
26.
S. Zakhari, Chronic alcohol drinking: Liver and pancreatic cancer?. Clin. Res. Hepatol. Gastroenterol. 39, 86–91 (2015)
27.
W. J. Choi, J. W. Lee, A. Cho, Y. J. Lee, Dose-Dependent Toxic Effect of Cotinine-Verified Tobacco Smoking on Systemic Inflammation in Apparently Healthy Men and Women: A Nationwide Population-Based Study. Int. J. Environ. Res. Public Health 16, 503 (2019)
28.
A. Ortega-Gómez, M. Perretti, O. Soehnlein, Resolution of inflammation: an integrated view. EMBO Mol. Med. 5, 661–674 (2013)
29.
C. D. Buckley, A. Filer, O. Haworth, G. Parsonage, M. Salmon, Defining a role for fibroblasts in the persistence of chronic inflammatory joint disease. Ann. Rheum. Dis. 63, 92–95 (2004)
30.
A. L. Mescher, Macrophages and fibroblasts during inflammation and tissue repair in models of organ regeneration. Regeneration 4, 39–53 (2017)
31.
J. Hartupee, D. L. Mann, Role of inflammatory cells in fibroblast activation. J. Mol. Cell Cardiol. 93, 143–148 (2016)
32.
F. G. Khalafalla, M. W. Khan, Inflammation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: Fighting against multiple opponents. Cancer Growth Metastasis 10, 117906441770928 (2017)
33.
Ł. Zadka, M. J. Kulus, K. Kurnol, A. Piotrowska, N. Glatzel-Plucińska, T. Jurek, M. Czuba, A. Nowak, M. Chabowski, D. Janczak, P. Dzięgiel, The expression of IL10RA in colorectal cancer and its correlation with the proliferation index and the clinical stage of the disease. Cytokine 110, 116–125 (2018)
34.
L. Heim, J. Friedrich, M. Engelhardt, D. I. Trufa, C. I. Geppert, R. J. Rieker, H. Sirbu, S. Finotto, NFATc1 promotes anti-tumoral effector functions and memory CD8+ T cell differentiation during non-small cell lung cancer development. Cancer Res. 78, 3619–3633 (2018)
35.
D. Valentini, M. Rao, Q. Meng, A. von Landenberg, J. Bartek, G. Sinclair, G. Paraschoudi, E. Jäger, I. Harvey-Peredo, E. Dodoo, M. Maeurer, Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma. Oncotarget 9, 19469–19480 (2018)
36.
M. V. Dieci, N. Radosevic-Robin, S. Fineberg, G. van den Eynden, N. Ternes, F. Penault-Llorca, G. Pruneri, T. M. D’Alfonso, S. Demaria, C. Castaneda, J. Sanchez, S. Badve, S. Michiels, V. Bossuyt, F. Rojo, B. Singh, T. Nielsen, G. Viale, S.-R. Kim, S. Hewitt, S. Wienert, S. Loibl, D. Rimm, F. Symmans, C. Denkert, S. Adams, S. Loi, R. Salgado, Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Bre. Semin. Cancer Biol. 52, 16–25 (2018)
37.
A. P. Ganesan, J. Clarke, O. Wood, E. M. Garrido-Martin, S. J. Chee, T. Mellows, D. Samaniego-Castruita, D. Singh, G. Seumois, A. Alzetani, E. Woo, P. S. Friedmann, E. V King, G. J. Thomas, T. Sanchez-Elsner, P. Vijayanand, C. H. Ottensmeier, Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat. Immunol. 18, 940–950 (2017)
38.
S. Matsutani, M. Shibutani, K. Maeda, H. Nagahara, T. Fukuoka, Y. Iseki, K. Hirakawa, M. Ohira, Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer. Oncotarget 9, 15180–15197 (2018)
39.
Y. Iseki, M. Shibutani, K. Maeda, H. Nagahara, T. Fukuoka, S. Matsutani, S. Kashiwagi, H. Tanaka, K. Hirakawa, M. Ohira, A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS One 13, e0192744 (2018)
40.
J. Li, Y. Tang, L. Huang, Q. Yu, G. Hu, Y. Zou, X. Yuan, A high number of stromal tumor-infiltrating lymphocytes is a favorable independent prognostic factor in M0 (stages I-III) esophageal squamous cell carcinoma. Dis. Esophagus 30, 1-7 (2016)
41.
C. Desmedt, R. Salgado, M. Fornili, G. Pruneri, G. Van den Eynden, G. Zoppoli, F. Rothé, L. Buisseret, S. Garaud, K. Willard-Gallo, D. Brown, Y. Bareche, G. Rouas, C. Galant, F. Bertucci, S. Loi, G. Viale, A. Di Leo, A. R. Green, I. O. Ellis, E. A. Rakha, D. Larsimont, E. Biganzoli, C. Sotiriou, Immune infiltration in invasive lobular breast cancer. JNCI J. Natl. Cancer Inst. 110, 768–776 (2018)
42.
C. Denkert, G. von Minckwitz, S. Darb-Esfahani, B. Lederer, B. I. Heppner, K. E. Weber, J. Budczies, J. Huober, F. Klauschen, J. Furlanetto, W. D. Schmitt, J. U. Blohmer, T. Karn, B. M. Pfitzner, S. Kümmel, K. Engels, A. Schneeweiss, A. Hartmann, A. Noske, P. A. Fasching, C. Jackisch, M. van Mackelenbergh, P. Sinn, C. Schem, C. Hanusch, M. Untch, S. Loibl, Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 19, 40–50 (2018)
43.
R. Ogiya, N. Niikura, N. Kumaki, G. Bianchini, S. Kitano, T. Iwamoto, N. Hayashi, K. Yokoyama, R. Oshitanai, M. Terao, T. Morioka, B. Tsuda, T. Okamura, Y. Saito, Y. Suzuki, Y. Tokuda, Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 107, 1730–1735 (2016)
44.
R. Kim, D. Coppola, E. Wang, Y. D. Chang, Y. Kim, D. Anaya, D. W. Kim, Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget 9, 23366–23372 (2018)
45.
S. M. Brunner, U. Hahn, T. Jeiter, R. Kesselring, C. Rubner, P. Ruemmele, Z. Sziklavari, H. S. Hofmann, H. J. Schlitt, S. Fichtner-Feigl, Immune architecture of colorectal lung metastases and implications for patient survival. Eur. Surg. Res. 57, 186–196 (2016)
46.
V. Krishnan, B. Schaar, S. Tallapragada, O. Dorigo, Tumor associated macrophages in gynecologic cancers. Gynecol. Oncol. 149, 205–213 (2018)
47.
A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, M. Locati, The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004)
48.
C. J. Ferrante, G. Pinhal-Enfield, G. Elson, B. N. Cronstein, G. Hasko, S. Outram, S. J. Leibovich, The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling Inflammation 36, 921–931 (2013)
49.
A. Kawachi, H. Yoshida, S. Kitano, Y. Ino, T. Kato, N. Hiraoka, Tumor-associated CD204 + M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. Cancer Sci. 109, 863–870 (2018)
50.
M. Alonso-Nocelo, T. M. Raimondo, K. H. Vining, R. López-López, M. de la Fuente, D. J. Mooney, Matrix stiffness and tumor-associated macrophages modulate epithelial to mesenchymal transition of human adenocarcinoma cells. Biofabrication 10, 035004 (2018)
51.
Y. Chen, H. Wen, C. Zhou, Q. Su, Y. Lin, Y. Xie, Y. Huang, Q. Qiu, J. Lin, X. Huang, W. Tan, C. Min, C. Wang, TNF-α derived from M2 tumor-associated macrophages promotes epithelial-mesenchymal transition and cancer stemness through the Wnt/β-catenin pathway in SMMC-7721 hepatocellular carcinoma cells. Exp. Cell Res. 378, 41–50 (2019)
52.
Y. C. Ye, J. L. Zhao, Y. T. Lu, C. C. Gao, Y. Yang, S. Q. Liang, Y. Y. Lu, L. Wang, S. Q. Yue, K. F. Dou, H. Y. Qin, H. Han, NOTCH signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res. 79, 4160–4172 (2019)
53.
J. Cai, L. Xia, J. Li, S. Ni, H. Song, X. Wu, Tumor-associated macrophages derived TGF-β–induced epithelial to mesenchymal transition in colorectal cancer cells through Smad2,3-4/Snail signaling pathway. Cancer Res. Treat. 51, 252–266 (2019)
54.
S. Chen, P. Zheng, W. Wang, M. Yi, P. Chen, J. Cai, J. Li, Q. Peng, Y. Ban, Y. Zhou, Z. Zeng, X. Li, W. Xiong, G. Li, B. Xiang, Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma. J. Cell Physiol. 233, 5002–5013 (2018)
55.
B. T. Copeland, H. Shallal, C. Shen, K. J. Pienta, C. A. Foss, M. G. Pomper, Imaging and characterization of macrophage distribution in mouse models of human prostate cancer. Mol. Imaging Biol. 21, 1054–1063 (2019)
56.
A. Valeta-Magara, A. Gadi, V. Volta, B. Walters, R. Arju, S. Giashuddin, H. Zhong, R. J. Schneider, Inflammatory breast cancer promotes development of M2 tumor-associated macrophages and cancer mesenchymal cells through a complex chemokine network. Cancer Res. 79, 3360–3371 (2019)
57.
L. Prasmickaite, E. M. Tenstad, S. Pettersen, S. Jabeen, E. V. Egeland, S. Nord, A. Pandya, M. H. Haugen, V. N. Kristensen, A. L. Børresen-Dale, O. Engebråten, G. M. Maelandsmo, Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4. Mol. Oncol. 12, 1540–1558 (2018)
58.
D. Di Mitri, M. Mirenda, J. Vasilevska, A. Calcinotto, N. Delaleu, A. Revandkar, V. Gil, G. Boysen, M. Losa, S. Mosole, E. Pasquini, R. D’Antuono, M. Masetti, E. Zagato, G. Chiorino, P. Ostano, A. Rinaldi, L. Gnetti, M. Graupera, A. R. Martins Figueiredo Fonseca, R. Pereira Mestre, D. Waugh, S. Barry, J. De Bono, A. Alimonti, Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 28, 2156–2168 (2019)
59.
E. Peranzoni, J. Lemoine, L. Vimeux, V. Feuillet, S. Barrin, C. Kantari-Mimoun, N. Bercovici, M. Guérin, J. Biton, H. Ouakrim, F. Régnier, A. Lupo, M. Alifano, D. Damotte, E. Donnadieu, Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proc. Natl. Acad. Sci. 115, 4041–4050 (2018)
60.
S. Borgoni, A. Iannello, S. Cutrupi, P. Allavena, M. D’Incalci, F. Novelli, P. Cappello, Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Oncoimmunology 7, e1393596 (2018)
61.
Y. Deng, Y. Yang, B. Yao, L. Ma, Q. Wu, Z. Yang, L. Zhang, B. Liu, Paracrine signaling by VEGF-C promotes non-small cell lung cancer cell metastasis via recruitment of tumor-associated macrophages. Exp. Cell Res. 364, 208–216 (2018)
62.
S. Li, F. Xu, J. Zhang, L. Wang, Y. Zheng, X. Wu, J. Wang, Q. Huang, M. Lai, Tumor-associated macrophages remodeling EMT and predicting survival in colorectal carcinoma. Oncoimmunology 7, e1380765 (2018)
63.
B. Mohebbi, K. Ashtibaghaei, M. Hashemi, M. Hashemi, H. Asadzadeh Aghdaei, M. R. Zali, Conditioned medium from cultured colorectal cancer cells affects peripheral blood mononuclear cells inflammatory phenotype in vitro. Iran J. Med. Sci. 44, 334–341 (2019)
64.
M. Kumari, M. P. Purohit, R. Pahuja, S. Patnaik, Y. Shukla, P. Kumar, K. C. Gupta, Pro-inflammatory macrophage polarization enhances the anti-cancer efficacy of self-assembled galactomannan nanoparticles entrapped with hydrazinocurcumin. Drug Deliv. Transl. Res. 9, 1159–1188 (2019)
65.
F. Kratochvill, G. Neale, J. M. Haverkamp, L. A. Van de Velde, A. M. Smith, D. Kawauchi, J. McEvoy, M. F. Roussel, M. A. Dyer, J. E. Qualls, P. J. Murray, TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 12, 1902–1914 (2015)
66.
R. B. Bednarczyk, N. Y. Tuli, E. K. Hanly, G. Ben Rahoma, R. Maniyar, A. Mittelman, J. Geliebter, R. K. Tiwari, Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer. Oncotarget 9, 24272–24282 (2018)
67.
K. A. Mouchemore, R. L. Anderson, J. A. Hamilton, Neutrophils, G-CSF and their contribution to breast cancer metastasis. FEBS J. 285, 665–679 (2018)
68.
Z. G. Fridlender, J. Sun, S. Kim, V. Kapoor, G. Cheng, L. Ling, G. S. Worthen, S. M. Albelda, Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell 16, 183–194 (2009)
69.
M. E. Shaul, Z. G. Fridlender, Cancer-related circulating and tumor-associated neutrophils – subtypes, sources and function. FEBS J. 285, 4316–4342 (2018)
70.
A. Barbetta, T. B. Nobel, S. Sihag, M. Hsu, K. S. Tan, M. S. Bains, J. M. Isbell, Y. Y. Janjigian, A. J. Wu, M. J. Bott, D. R. Jones, D. Molena, Neutrophil to lymphocyte ratio as predictor of treatment response in esophageal squamous cell cancer. Ann. Thorac. Surg. 106, 864–871 (2018)
71.
S. Taguchi, H. Fukuhara, J. Miyakawa, T. Morikawa, A. Naito, T. Kawai, T. Fujimura, H. Kume, Prognostic significance of neutrophil-to-lymphocyte ratio in collecting duct carcinoma. Jpn. J. Clin. Oncol. 48, 692–694 (2018)
72.
K. Liu, K. Zhao, L. Wang, E. Sun, The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer. Pathol. Res. Pract. 214, 1074–1080 (2018)
73.
Y. Morizawa, M. Miyake, K. Shimada, S. Hori, Y. Tatsumi, Y. Nakai, S. Onishi, N. Tanaka, N. Konishi, K. Fujimoto, Correlation of immune cells and cytokines in the tumor microenvironment with elevated neutrophil-to-lymphocyte ratio in blood: An analysis of muscle-invasive bladder cancer. Cancer Invest. 36, 395–405 (2018)
74.
Y. Kitano, H. Okabe, Y. Yamashita, S. Nakagawa, Y. Saito, N. Umezaki, M. Tsukamoto, T. Yamao, K. Yamamura, K. Arima, T. Kaida, T. Miyata, K. Mima, K. Imai, D. Hashimoto, Y. Komohara, A. Chikamoto, T. Ishiko, H. Baba, Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. Br. J. Cancer 118, 171–180 (2018)
75.
C. L. Chen, Y. Wang, C. Y. Huang, Z. Q. Zhou, J. J. Zhao, X. F. Zhang, Q. Z. Pan, J. X. Wu, D. S. Weng, Y. Tang, Q. Zhu, L. P. Yuan, J. C. Xia, IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. Oncoimmunology 7, e1373234 (2018)
76.
S. Mensurado, M. Rei, T. Lança, M. Ioannou, N. Gonçalves-Sousa, H. Kubo, M. Malissen, V. Papayannopoulos, K. Serre, B. Silva-Santos, Tumor-associated neutrophils suppress pro-tumoral IL-17+ γδ T cells through induction of oxidative stress. PLOS Biol. 16, e2004990 (2018)
77.
C. M. Rice, L. C. Davies, J. J. Subleski, N. Maio, M. Gonzalez-Cotto, C. Andrews, N. L. Patel, E. M. Palmieri, J. M. Weiss, J. M. Lee, C. M. Annunziata, T. A. Rouault, S. K. Durum, D. W. McVicar, Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression. Nat. Commun. 9, 5099 (2018)
78.
P. Qu, L. Wang, P. C. Lin, Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Lett. 380, 253–256 (2016)
79.
M. Bauswein, A. Singh, A. Ralhan, D. Neri, K. Fuchs, K. D. Blanz, I. Schäfer, A. Hector, R. Handgretinger, D. Hartl, N. Rieber, Human T cells modulate myeloid-derived suppressor cells through a TNF-α-mediated mechanism. Immunol. Lett. 202 31–37 (2018)
80.
H. Shi, X. Han, Y. Sun, C. Shang, M. Wei, X. Ba, X. Zeng, Chemokine (C-X-C motif) ligand 1 and CXCL2 produced by tumor promote the generation of monocytic myeloid-derived suppressor cells. Cancer Sci. 109, 3826–3839 (2018)
81.
X. Guan, Z. Liu, J. Zhang, X. Jin, Myeloid-derived suppressor cell accumulation in renal cell carcinoma is correlated with CCL2, IL-17 and IL-18 expression in blood and tumors. Adv. Clin. Exp. Med. 27, 947–953 (2018)
82.
T. Yan, G. H. Zhang, Y. Z. Cheng, L. X. Wu, X. Y. Liu, Y. L. Sun, H. Zheng, L. Sun, Effects of anesthetic technique and surgery on myeloid-derived suppressor cells and prognosis in women who underwent breast cancer surgery: a prospective study. Cancer Manag. Res. 11, 5513–5522 (2019)
83.
T. Baert, A. Vankerckhoven, M. Riva, A. Van Hoylandt, G. Thirion, G. Holger, T. Mathivet, I. Vergote, A. Coosemans, Myeloid derived suppressor cells: Key drivers of immunosuppression in ovarian cancer. Front Immunol. 10, 1273 (2019)
84.
M. Taki, K. Abiko, T. Baba, J. Hamanishi, K. Yamaguchi, R. Murakami, K. Yamanoi, N. Horikawa, Y. Hosoe, E. Nakamura, A. Sugiyama, M. Mandai, I. Konishi, N. Matsumura, Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat. Commun. 9, 1685 (2018)
85.
Y. L. Hsu, M. C. Yen, W. A. Chang, P. H. Tsai, Y. C. Pan, S. H. Liao, P. L. Kuo, CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB. Breast Cancer Res. 21, 23 (2019)
86.
S. Kumar, D. W. Wilkes, N. Samuel, M. A. Blanco, A. Nayak, K. Alicea-Torres, C. Gluck, S. Sinha, D. Gabrilovich, R. Chakrabarti, ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J. Clin. Invest. 128, 5095–5109 (2018)
87.
L. Sun, P. E. Clavijo, Y. Robbins, P. Patel, J. Friedman, S. Greene, R. Das, C. Silvin, C. Van Waes, L. A. Horn, J. Schlom, C. Palena, D. Maeda, J. Zebala, C. T. Allen, Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight 4, e126853 (2019)
88.
P. Ma, P. L. Beatty, J. McKolanis, R. Brand, R. E. Schoen, O. J. Finn, Circulating myeloid derived suppressor cells (MDSC) that accumulate in premalignancy share phenotypic and functional characteristics with MDSC in cancer. Front Immunol. 10, 1401 (2019)
89.
F. Mao, Y. Zhao, Y. Lv, Y. Teng, H. Kong, Y. Liu, X. Wu, C. Hao, W. Chen, M. Duan, B. Han, Q. Ma, T. Wang, L. Peng, J. Zhang, P. Cheng, C. Su, X. Fu, Q. Zou, G. Guo, X. Guo, Y. Zhuang, CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer. Cell Death Dis. 9, 763 (2018)
90.
Z. Bian, A. M. Abdelaal, L. Shi, H. Liang, L. Xiong, K. Kidder, M. Venkataramani, C. Culpepper, K. Zen, Y. Liu, Arginase-1 is neither constitutively expressed in nor required for myeloid-derived suppressor cell-mediated inhibition of T-cell proliferation. Eur. J. Immunol. 48, 1046–1058 (2018)
91.
E. Jachetti, V. Cancila, A. Rigoni, L. Bongiovanni, B. Cappetti, B. Belmonte, C. Enriquez, P. Casalini, P. Ostano, B. Frossi, S. Sangaletti, C. Chiodoni, G. Chiorino, C. E. Pucillo, C. Tripodo, M. P. Colombo, Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol. Res. 6, 552–565 (2018)
92.
K. Okła, A. Czerwonka, A. Wawruszak, M. Bobiński, M. Bilska, R. Tarkowski, W. Bednarek, I. Wertel, J. Kotarski, Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer. Front Immunol. 10, 691 (2019)
93.
A. Li, H. B. Barsoumian, J. E. Schoenhals, M. S. Caetano, X. Wang, H. Menon, D. R. Valdecanas, S. Niknam, A. I. Younes, M. A. Cortez, J. W. Welsh, IDO1 inhibition overcomes radiation-induced “Rebound Immune Suppression” by reducing numbers of IDO1-expressing myeloid-derived suppressor cells in the tumor microenvironment. Int. J. Radiat. Oncol. 104, 903–912 (2019)
94.
S. Nam, A. Lee, J. Lim, J. S. Lim, Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). Biomol. Ther. 27, 63–70 (2019)
95.
R. Hellsten, L. Lilljebjörn, M. Johansson, K. Leandersson, A. Bjartell, The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. Prostate 79, 1611–1621 (2019)
96.
P. Guha, J. Gardell, J. Darpolor, M. Cunetta, M. Lima, G. Miller, N. J. Espat, R. P. Junghans, S. C. Katz, STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Oncogene 38, 533–548 (2019)
97.
D. Joyce, M. Fujino, M. Morita, R. Araki, J. Fung, S. Qian, L. Lu, X. K. Li, Induced pluripotent stem cells-derived myeloid-derived suppressor cells regulate the CD8 + T cell response. Stem Cell Res. 29, 32–41 (2018)
98.
T. Shimura, M. Shibata, K. Gonda, S. Hayase, W. Sakamoto, H. Okayama, S. Fujita, M. Saito, T. Momma, S. Ohki, K. Kono, Prognostic impact of preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer with special reference to myeloid-derived suppressor cells. FUKUSHIMA J. Med. Sci. 64, 64–72 (2018)
99.
K. Jiang, J. Li, J. Zhang, L. Wang, Q. Zhang, J. Ge, Y. Guo, B. Wang, Y. Huang, T. Yang, D. Hao, L. Shan, SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Int. Immunopharmacol. 75, 105818 (2019)
100.
G. Yan, H. Zhao, Q. Zhang, Y. Zhou, L. Wu, J. Lei, X. Wang, J. Zhang, X. Zhang, L. Zheng, G. Du, W. Xiao, B. Tang, H. Miao, Y. Li, A RIPK3-PGE 2 circuit mediates myeloid-derived suppressor cell–potentiated colorectal carcinogenesis. Cancer Res. 78, 5586–5599 (2018)
101.
M. Ma, W. Huang, D. Kong, IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3. Int. Immunopharmacol. 59, 148–156 (2018)
102.
Y. Deng, J. Yang, J. Qian, R. Liu, E. Huang, Y. Wang, F. Luo, Y. Chu, TLR1/TLR2 signaling blocks the suppression of monocytic myeloid-derived suppressor cell by promoting its differentiation into M1-type macrophage. Mol. Immunol. 112, 266–273 (2019)
103.
Y. C. Cheong, W. L. Ledger, Cytokines in health and disease. Obstet. Gynaecol. 5, 155–159 (2003)
104.
C. Jandl, C. Loetsch, C. King, Cytokine expression by T follicular helper cells. Methods Mol. Biol. (Humana Press, New York, 2017), pp. 95–103
105.
H. Shirota, D. M. Klinman, S. Ito, H. Ito, M. Kubo, et al., IL4 from T follicular helper cells downregulates antitumor immunity. Cancer Immunol. Res. 5, 61–71 (2017)
106.
H. Wang, X. Yang, Association between serum cytokines and progression of breast cancer in Chinese population. Medicine (Baltimore) 96, e8840 (2017)
107.
S. I. Grivennikov, M. Karin, Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 70, 104–108 (2011)
108.
I. Penn, T.E. Starzl, Proceedings: The effect of immunosuppression on cancer. Proc. Natl. Cancer Conf. 7, 425–436 (1972)
109.
P. Lamichhane, L. Karyampudi, B. Shreeder, J. Krempski, D. Bahr, J. Daum, K. R. Kalli, E. L. Goode, M. S. Block, M. J. Cannon, K. L. Knutson, IL10 Release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res. 77, 6667–6678 (2017)
110.
L. Castiello, M. Sabatino, J. Ren, M. Terabe, H. Khuu, L. V. Wood, J. A. Berzofsky, D. F. Stroncek, Expression of CD14, IL10, and tolerogenic signature in dendritic cells inversely correlate with clinical and immunologic response to TARP vaccination in prostate cancer patients. Clin. Cancer Res. 23, 3352–3364 (2017)
111.
J. Du, Y. Yu, J. Zhan, H. Zhang, Targeted therapies against growth factor signaling in breast cancer. (Springer, Singapore, 2017), pp. 125–146
112.
X. Chen, J. Wang, R. Wang, Q. Su, J. Luan, H. Huang, P. Zhou, J. Liu, X. Xu, Th1-, Th2-, and Th17-associated cytokine expression in hypopharyngeal carcinoma and clinical significance. Eur. Arch. Oto-Rhino-Laryngology 273, 431–438 (2016)
113.
A. Jarnicki, T. Putoczki, M. Ernst, Stat3: linking inflammation to epithelial cancer - more than a “gut” feeling? Cell Div. 5, 14 (2010)
114.
T. Tanaka, M. Narazaki, T. Kishimoto, IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect Biol. 6, a016295 (2014)
115.
J. Wolf, S. Rose-John, C. Garbers, Interleukin-6 and its receptors: A highly regulated and dynamic system. Cytokine 70, 11–20 (2014)
116.
R. Sabat, IL-10 family of cytokines. Cytokine Growth Factor Rev. 21, 315–324 (2010)
117.
R. Sabat, G. Grütz, K. Warszawska, S. Kirsch, E. Witte, K. Wolk, J. Geginat, Biology of interleukin-10. Cytokine Growth Factor Rev. 21, 331–344 (2010)
118.
X. Wang, K. Wong, W. Ouyang, S. Rutz, Targeting IL-10 Family Cytokines for the treatment of human diseases. Cold Spring Harb Perspect Biol. 11, a028548 (2019)
119.
P. Hsu, B. Santner-Nanan, M. Hu, K. Skarratt, C. H. Lee, M. Stormon, M. Wong, S. J. Fuller, R. Nanan, IL-10 potentiates differentiation of human induced regulatory T cells via STAT3 and Foxo1. J. Immunol. 195, 3665–3674 (2015)
120.
B. Koscsó, B. Csóka, E. Kókai, Z. H. Németh, P. Pacher, L. Virág, S. J. Leibovich, G. Haskó, Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages. J. Leukoc. Biol. 94, 1309–1315 (2013)
121.
A. V Villarino, Y. Kanno, J. J. O’Shea, Mechanisms and consequences of Jak–STAT signaling in the immune system. Nat. Immunol. 18, 374–384 (2017)
122.
K. Takeda, S. Akira, STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev. 11, 199–207 (2000)
123.
J. Braunstein, S. Brutsaert, R. Olson, C. Schindler, STATs dimerize in the absence of phosphorylation. J. Biol. Chem. 278, 34133–34140 (2003)
124.
O. K. Park, L. K. Schaefer, W. Wang, T. S. Schaefer, Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms. J. Biol. Chem. 275, 32244–32249 (2000)
125.
E. Butturini, G. Gotte, D. Dell’Orco, G. Chiavegato, V. Marino, D. Canetti, F. Cozzolino, M. Monti, P. Pucci, S. Mariotto, Intermolecular disulfide bond influences unphosphorylated STAT3 dimerization and function. Biochem. J. 473, 3205–3219 (2016)
126.
J. Geginat, P. Larghi, M. Paroni, G. Nizzoli, A. Penatti, M. Pagani, N. Gagliani, P. Meroni, S. Abrignani, R. A. Flavell, The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. Cytokine Growth Factor Rev. 30, 87–93 (2016)
127.
L. Williams, L. Bradley, A. Smith, B. Foxwell, Signal Transducer and activator of Transcription 3 Is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172, 567–576 (2004)
128.
M. Kortylewski, M. Kujawski, T. Wang, S. Wei, S. Zhang, S. Pilon-Thomas, G. Niu, H. Kay, J. Mulé, W. G. Kerr, R. Jove, D. Pardoll, H. Yu, Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314–1321 (2005)
129.
D. M. S. Hossain, A. K. Panda, A. Manna, S. Mohanty, P. Bhattacharjee, S. Bhattacharyya, T. Saha, S. Chakraborty, R. K. Kar, T. Das, S. Chatterjee, G. Sa, FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. Immunity 39, 1057–1069 (2013)
130.
N. P. Bgatova, A. I. Lomakin, S. A. Fursov, I. V. Kachesov, S. A. Chepko, N. B. Isakova, Y. I. Borodin, V. E. Voytsitsky, V. I. Konenkov, Expression of molecular markers of angiogenesis, lymphangiogenesis, and proliferation depending on the stage of skin melanoma. Bull Exp. Biol. Med. 161, 542–546 (2016)
131.
K. Hirota, G. L. Semenza, Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59, 15–26 (2006)
132.
L. Kafshdooz, A. D. Tabrizi, S. M. Mohaddes, T. Kafshdooz, A. Akbarzadeh, M. Ghojazadeh, J. Gharesouran, The polymorphism of hypoxia-inducible factor-1a gene in endometrial cancer. Asian Pacific J. Cancer Prev. 15, 10393–10396 (2015)
133.
H. E. Turner, A. L. Harris, S. Melmed, J. A. H. Wass, Angiogenesis in endocrine tumors. Endocr. Rev. 24, 600–632 (2003)
134.
S. Ramakrishnan, V. Anand, S. Roy, Vascular endothelial growth factor signaling in hypoxia and inflammation. J. Neuroimmune Pharmacol. 9, 142–160 (2014)
135.
B. L. Krock, N. Skuli, M. C. Simon, Hypoxia-induced angiogenesis: Good and evil. Genes Cancer 2, 1117–1133 (2011)
136.
F. Luo, Z. Zou, X. Liu, M. Ling, Q. Wang, Q. Wang, L. Lu, L. Shi, Y. Liu, Q. Liu, A. Zhang, Enhanced glycolysis, regulated by HIF-1α via MCT-4, promotes inflammation in arsenite-induced carcinogenesis. Carcinogenesis 38, 615–626 (2017)
137.
D. N. Mladenova, J. E. Dahlstrom, P. N. Tran, F. Benthani, E. G. Bean, I. Ng, L. Pangon, N. Currey, M. R. J. Kohonen-Corish, HIF1α deficiency reduces inflammation in a mouse model of proximal colon cancer. Dis. Model Mech. 8, 1093–1103 (2015)
138.
E. Rad, K. Dodd, L. Thomas, M. Upadhyaya, A. Tee, STAT3 and HIF1 signaling drives oncogenic cellular phenotypes in malignant peripheral nerve sheath tumors. Mol. Cancer Res. 13, 1149–1160 (2015)
139.
S. E. Stanton, M. L. Disis, Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J. Immunother. Cancer 4, 59 (2016)
140.
K. N. Townsend, J. E. Spowart, H. Huwait, S. Eshragh, N. R. West, M. A. Elrick, S. E. Kalloger, M. Anglesio, P. H. Watson, D. G. Huntsman, J. J. Lum, Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous varian carcinoma. PLoS One, 8, e82406 (2013)
141.
S.A. Budda, A. Girton, J.G. Henderson, L.A. Zenewicz, Transcription factor HIF-1α controls expression of the cytokine IL-22 in CD4 T cells. J. Immunol. 197, 2646–2652 (2016)
142.
A. Ridiandries, J.T.M. Tan, D. Ravindran, H. Williams, H.J. Medbury, L. Lindsay, C. Hawkins, H.C.G. Prosser, C.A. Bursill, CC-chemokine class inhibition attenuates pathological angiogenesis while preserving physiological angiogenesis. FASEB J. 31, 1179–1192 (2017)
143.
J.B. Xia, G.H. Liu, Z.Y. Chen, C.Z. Mao, D.C. Zhou, H.Y. Wu, K.S. Park, H. Zhao, S.K. Kim, D.Q. Cai, X.F. Qi, Hypoxia/ischemia promotes CXCL10 expression in cardiac microvascular endothelial cells by NFkB activation. Cytokine 81, 63–70 (2016)
144.
J. Richards, K. Gabunia, S.E. Kelemen, F. Kako, E.T. Choi, M.V. Autieri, Interleukin-19 increases angiogenesis in ischemic hind limbs by direct effects on both endothelial cells and macrophage polarization. J. Mol. Cell Cardiol. 79, 21–31 (2015)
145.
F. Kako, K. Gabunia, M. Ray, S.E. Kelemen, R.N. England, B. Kako, R.G. Scalia, M.V. Autieri, Interleukin-19 induces angiogenesis in the absence of hypoxia by direct and indirect immune mechanisms. Am. J. Physiol. Cell Physiol 310, C931 (2016)
146.
M. Climent, É.J. Ryan, Á. Stakelum, Y.L. Khaw, B. Creavin, A. Lloyd, D. Alhassan, H.M. Mohan, R. Kennelly, K. Sheahan, D.C. Winter, Src contributes to IL6-induced vascular endothelial growth factor-C expression in lymphatic endothelial cells. Angiogenesis 17, 407–418 (2014)
147.
F. Schaper, S. Rose-John, Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 26, 475–487 (2015)
148.
B. Jiang, S.J. Zhu, S.S. Xiao, M. Xue, MiR-217 inhibits M2-like macrophage polarization by suppressing secretion of interleukin-6 in ovarian cancer. Inflammation 42, 1517–1529 (2019)
149.
P. Ortiz-Montero, A. Londoño-Vallejo, J.P. Vernot, Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun. Signal 15, 17 (2017)
150.
M.K. Ruhland, A.J. Loza, A.H. Capietto, X. Luo, B.L. Knolhoff, K.C. Flanagan, B.A. Belt, E. Alspach, K. Leahy, J. Luo, A. Schaffer, J.R. Edwards, G. Longmore, R. Faccio, D.G. DeNardo, S.A. Stewart, Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 7, 11762 (2016)
151.
T. Zhou, Y. Zhou, M. Qian, Y. Fang, S. Ye, W. Xin, X. Yang, H. Wu, Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumor-associated macrophages. J. Pharmacol. Sci. 138, 89–95 (2018)
152.
C. Zenobia, G. Hajishengallis, Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol. 2000(69), 142–159 (2015)
153.
S. Razi, B. Baradaran Noveiry, M. Keshavarz-Fathi, N. Rezaei, IL-17 and colorectal cancer: From carcinogenesis to treatment. Cytokine 116, 7–12 (2019)
154.
A. Korobowicz, [Biology of tumor necrosis factor type alpha (TNF-alpha)]. Pol. Merkur. Lekarski. 21, 358–361 (2006)
155.
Y. Lv, Y. Zhao, X. Wang, N. Chen, F. Mao, Y. Teng, T. Wang, L. Peng, J. Zhang, P. Cheng, Y. Liu, H. Kong, W. Chen, C. Hao, B. Han, Q. Ma, Q. Zou, J. Chen, Y. Zhuang, Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway. J. Immunother. Cancer 7, 54 (2019)
156.
G. Palmer, C. Gabay, Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 7, 321–329 (2011)
157.
K. Wang, S. Shan, Z. Yang, X. Gu, Y. Wang, C. Wang, T. Ren, IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model. Oncotarget 8, 68571–68582 (2017)
158.
C. Dreis, F.M. Ottenlinger, M. Putyrski, A. Ernst, M. Huhn, K.G. Schmidt, J.M. Pfeilschifter, H.H. Radeke, Tissue cytokine IL-33 modulates the cytotoxic CD8 T lymphocyte activity during nutrient deprivation by regulation of lineage-specific differentiation programs. Front Immunol. 10, 1698 (2019)
159.
E. Tu, P.Z.C. Chia, W. Chen, TGFβ in T cell biology and tumor immunity: Angel or devil? Cytokine Growth Factor Rev. 25, 423–435 (2014)
160.
A. Gonzalez-Junca, K.E. Driscoll, I. Pellicciotta, S. Du, C.H. Lo, R. Roy, R. Parry, I. Tenvooren, D.M. Marquez, M.H. Spitzer, M.H. Barcellos-Hoff, Autocrine TGFβ is a survival factor for monocytes and drives immunosuppressive lineage commitment. Cancer Immunol. Res. 7(306–320) (2019)
161.
X. Chen, L. Wang, P. Li, M. Song, G. Qin, Q. Gao, Z. Zhang, D. Yue, D. Wang, S. Nan, Y. Qi, F. Li, L. Yang, L. Huang, M. Zhang, B. Zhang, Y. Gao, Y. Zhang, Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 + T cell response in esophageal squamous cell carcinoma. Int. J. Cancer 143, 2561–2574 (2018)
162.
I. Cohen, P. Rider, Y. Carmi, A. Braiman, S. Dotan, M.R. White, E. Voronov, M.U. Martin, C.A. Dinarello, R.N. Apte, Differential release of chromatin-bound IL-1 discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. 107, 2574–2579 (2010)
163.
P. Rider, Y. Carmi, O. Guttman, A. Braiman, I. Cohen, E. Voronov, M.R. White, C.A. Dinarello, R.N. Apte, IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 187, 4835–4843 (2011)
164.
R. Shrivastava, V. Singh, M. Asif, M.P.S. Negi, S. Bhadauria, Oncostatin M upregulates HIF-1α in breast tumor associated macrophages independent of intracellular oxygen concentration. Life Sci. 194, 59–66 (2018)
165.
L. Lau, A. Porciuncula, A. Yu, Y. Iwakura, G. David, Uncoupling the senescence-associated secretory phenotype from cell cycle exit via interleukin-1 inactivation unveils its protumorigenic role. Mol. Cell Biol. 39, pii: e00586–18 (2019)
166.
M. Climent, É.J. Ryan, Á. Stakelum, Y.L. Khaw, B. Creavin, A. Lloyd, D. Alhassan, H.M. Mohan, R. Kennelly, K. Sheahan, D.C. Winter, Systemic inflammatory response predicts oncological outcomes in patients undergoing elective surgery for mismatch repair-deficient colorectal cancer. Int. J. Colorectal. Dis. 34, 1069–1078 (2019)
167.
B. Li, Y. Liu, T. Hu, Y. Zhang, C. Zhang, T. Li, C. Wang, Z. Dong, V.A. Novakovic, T. Hu, J. Shi, Neutrophil extracellular traps enhance procoagulant activity in patients with oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 145, 1695–1707 (2019)
168.
A. Fabian, S. Stegner, L. Miarka, J. Zimmermann, L. Lenk, S. Rahn, J. Buttlar, F. Viol, H. Knaack, D. Esser, S. Schäuble, P. Großmann, G. Marinos, R. Häsler, W. Mikulits, D. Saur, C. Kaleta, H. Schäfer, S. Sebens, Metastasis of pancreatic cancer: An uninflamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreatic ductal epithelial cells. Cancer Lett. 453, 95–106 (2019)
169.
A. Varkaris, A. Katsiampoura, J.S. Davis, N. Shah, M. Lam, R.L. Frias, C. Ivan, M. Shimizu, J. Morris, D. Menter, M. Overman, H. Tran, J. Heymach, Y.S. Chun, J.N. Vauthey, G. Calin, S. Kopetz, Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br. J. Cancer 120, 340–345 (2019)
170.
A. Katsura, Y. Tamura, S. Hokari, M. Harada, M. Morikawa, T. Sakurai, K. Takahashi, A. Mizutani, J. Nishida, Y. Yokoyama, Y. Morishita, T. Murakami, S. Ehata, K. Miyazono, D. Koinuma, ZEB1-regulated inflammatory phenotype in breast cancer cells. Mol. Oncol. 11, 1241–1262 (2017)
171.
Z. Dou, K. Ghosh, M.G. Vizioli, J. Zhu, P. Sen, K.J. Wangensteen, J. Simithy, Y. Lan, Y. Lin, Z. Zhou, B.C. Capell, C. Xu, M. Xu, J.E. Kieckhaefer, T. Jiang, M. Shoshkes-Carmel, K.M.A. Al Tanim, G.N. Barber, J.T. Seykora, S.E. Millar, K.H. Kaestner, B.A. Garcia, P.D. Adams, S.L. Berger, Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402–406 (2017)
172.
E. Mavrogonatou, H. Pratsinis, D. Kletsas, The role of senescence in cancer development. Semin Cancer Biol. 62, 182–191 (2019)
173.
J.P. Coppé, C.K. Patil, F. Rodier, Y. Sun, D.P. Muñoz, J. Goldstein, P.S. Nelson, P.Y. Desprez, J. Campisi, Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, e301 (2008)
174.
V. Rohnalter, K. Roth, F. Finkernagel, T. Adhikary, J. Obert, K. Dorzweiler, M. Bensberg, S. Müller-Brüsselbach, R. Müller, A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget 6, 40005–40025 (2015)
175.
N. Alessio, D. Aprile, T. Squillaro, G. Di Bernardo, M. Finicelli, M.A. Melone, G. Peluso, U. Galderisi, The senescence-associated secretory phenotype (SASP) from mesenchymal stromal cells impairs growth of immortalized prostate cells but has no effect on metastatic prostatic cancer cells. Aging (Albany. NY) 11, 5817–5828 (2019)
176.
S.K. Ramraj, K.M. Smith, N.B. Janakiram, C. Toal, A. Raman, D.M. Benbrook, Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell 52, 57–64 (2018)
177.
Y. Wu, S. Antony, J.L. Meitzler, J.H. Doroshow, Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett. 345, 164–173 (2014)
178.
M. Bettonville, S. D’Aria, K. Weatherly, P.E. Porporato, J. Zhang, S. Bousbata, P. Sonveaux, M. Y. Braun, Long-term antigen exposure irreversibly modifies metabolic requirements for T cell function. Elife 7, pii: e30938 (2018)
179.
M. Chechlinska, M. Kowalewska, R. Nowak, Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat. Rev. Cancer 10, 2–3 (2010)
180.
M. Lario, L. Muñoz, M. Ubeda, M.J. Borrero, J. Martínez, J. Monserrat, D. Díaz, M. Álvarez-Mon, A. Albillos, Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis. J. Hepatol. 59, 723–730 (2013)
181.
K. Li, H. Liu, T. Guo, Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients. Clin. Res. Hepatol. Gastroenterol. 41, 399–407 (2017)
182.
S. Shalapour, X.J. Lin, I.N. Bastian, J. Brain, A.D. Burt, A.A. Aksenov, A.F. Vrbanac, W. Li, A. Perkins, T. Matsutani, Z. Zhong, D. Dhar, J.A. Navas-Molina, J. Xu, R. Loomba, M. Downes, R.T. Yu, R.M. Evans, P.C. Dorrestein, R. Knight, C. Benner, Q.M. Anstee, M. Karin, Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551, 340–345 (2017)
183.
J. Peter, O. Frey, A. Stallmach, T. Bruns, Attenuated antigen-specific T cell responses in cirrhosis are accompanied by elevated serum interleukin-10 levels and down-regulation of HLA-DR on monocytes. BMC Gastroenterol. 13, 37 (2013)
184.
F. Li, N. Li, J. Sang, X. Fan, H. Deng, X. Zhang, Q. Han, Y. Lv, Z. Liu, Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection. Cancer Manag. Res. 10, 941–951 (2018)
185.
Y.H. Huang, C. Zhu, Y. Kondo, A.C. Anderson, A. Gandhi, A. Russell, S.K. Dougan, B.S. Petersen, E. Melum, T. Pertel, K.L. Clayton, M. Raab, Q. Chen, N. Beauchemin, P.J. Yazaki, M. Pyzik, M.A. Ostrowski, J.N. Glickman, C.E. Rudd, H.L. Ploegh, A. Franke, G.A. Petsko, V.K. Kuchroo, R.S. Blumberg, CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517, 386–390 (2015)
186.
B. Delire, P. Henriet, P. Lemoine, I.A. Leclercq, P. Stärkel, Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages. Cancer Sci. 109, 2141–2152 (2018)
187.
C.J. Lim, Y.H. Lee, L. Pan, L. Lai, C. Chua, M. Wasser, T.K.H. Lim, J. Yeong, H.C. Toh, S.Y. Lee, C.Y. Chan, B.K. Goh, A. Chung, M. Heikenwälder, I.O. Ng, P. Chow, S. Albani, V. Chew, Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 68, 916–927 (2019)
188.
Y. Kurebayashi, H. Ojima, H. Tsujikawa, N. Kubota, J. Maehara, Y. Abe, M. Kitago, M. Shinoda, Y. Kitagawa, M. Sakamoto, Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 68, 1025–1041 (2018)
189.
T. Flecken, N. Schmidt, S. Hild, E. Gostick, O. Drognitz, R. Zeiser, P. Schemmer, H. Bruns, T. Eiermann, D.A. Price, H.E. Blum, C. Neumann-Haefelin, R. Thimme, Immunodominance and functional alterations of tumor-associated antigen-specific CD8 + T-cell responses in hepatocellular carcinoma. Hepatology 59, 1415–1426 (2014)
190.
J. Li, Y. Lee, Y. Li, Y. Jiang, H. Lu, W. Zang, X. Zhao, L. Liu, Y. Chen, H. Tan, Z. Yang, M.Q. Zhang, T.W. Mak, L. Ni, C. Dong, Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells. Immunity 48, 773–786 (2018)
191.
D. Teng, L. Ding, B. Cai, Q. Luo, H. Wang, Interleukin-7 enhances anti-tumor activity of CD8+ T cells in patients with hepatocellular carcinoma. Cytokine 118, 115–123 (2019)
192.
M. He, Y. Le, Y. Zhang, H. Ouyang, P. Jian, Z. Yu, L. Wang, M. Shi, Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma. Oncol. Lett. 16, 475–482 (2018)
193.
Y.T. Lan, X.P. Fan, Y.C. Fan, J. Zhao, K. Wang, Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value. Medicine 96, e7704 (2017)
194.
H.R. Liu, W.M. Li, Treg-specific demethylated region activity in isolated regulatory t lymphocytes is a surrogate for disease severity in hepatocellular carcinoma. IUBMB Life 67, 355–360 (2015)
195.
Y. Han, Y. Yang, Z. Chen, Z. Jiang, Y. Gu, Y. Liu, S. Xu, C. Lin, Z. Pan, W. Zhou, X. Cao, Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3− regulatory T cell suppresses T cell response via membrane-bound TGF-β1. J. Mol. Med. 92, 539–550 (2014)
196.
Y. Shen, Y. Wei, Z. Wang, Y. Jing, H. He, J. Yuan, R. Li, Q. Zhao, L. Wei, T. Yang, J. Lu, TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol. Biochem. 35, 1623–1632 (2015)
197.
K.S. Smigiel, S. Srivastava, J.M. Stolley, D.J. Campbell, Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol. Rev. 259, 40–59 (2014)
198.
A. Metelli, B.X. Wu, C.W. Fugle, S. Rachidi, S. Sun, Y. Zhang, J. Wu, S. Tomlinson, P.H. Howe, Y. Yang, E. Garrett-Mayer, B. Liu, Z. Li, Surface expression of TGFβ docking receptor GARP promotes oncogenesis and immune tolerance in breast cancer. Cancer Res. 76, 7106–7117 (2016)
199.
Y. Cheng, H. Li, Y. Deng, Y. Tai, K. Zeng, Y. Zhang, W. Liu, Q. Zhang, Y. Yang, Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 9, 422 (2018)
200.
R.R. Yao, J.H. Li, R. Zhang, R.X. Chen, Y.H. Wang, M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. World J. Surg. Oncol. 16, 9 (2018)
201.
J. Jupp, S. Mansour, C.D. Johnson, J. Sanderson, D. Fine, S. Gadola, T-cell populations in chronic pancreatitis. Pancreatology 15, 311–312 (2015)
202.
M. Sasikala, V. Ravikanth, K. Murali Manohar, N. Deshpande, S. Singh, P. Pavan Kumar, R. Talukdar, S. Ghosh, M. Aslam, G. Rao, R. Pradeep, D.N. Reddy, Bach2 repression mediates Th17 cell induced inflammation and associates with clinical features of advanced disease in chronic pancreatitis. United Eur. Gastroenterol. J. 6, 272–282 (2018)
203.
H. Schmitz-Winnenthal, D. K. Pietsch, S. Schimmack, A. Bonertz, F. Udonta, Y. Ge, L. Galindo, S. Specht, C. Volk, K. Zgraggen, M. Koch, M. W. Büchler, J. Weitz, P. Beckhove, Chronic pancreatitis is associated with disease-specific regulatory T-cell responses. Gastroenterology 138, 1178–1188 (2010)
204.
E.K. Choi, M.H. Kim, S.J. Jang, K.H. Lee, C.Y. Hwang, S.H. Moon, T.Y. Lee, C.O. Koh, D.H. Park, S.S. Lee, D.W. Seo, S.K. Lee, Differences in pancreatic immunohistochemical staining profiles of TGF-β1, MMP-2, and TIMP-2 between autoimmune and alcoholic chronic pancreatitis. Pancreas 38, 739–745 (2009)
205.
F. Bengsch, D.M. Knoblock, A. Liu, F. McAllister, G.L. Beatty, CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol. Immunother. 66, 1609–1617 (2017)
206.
J.E. Jang, C.H. Hajdu, C. Liot, G. Miller, M.L. Dustin, D. Bar-Sagi, Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 20, 558–571 (2017)
207.
P. Lohneis, M. Sinn, S. Bischoff, A. Jühling, U. Pelzer, L. Wislocka, M. Bahra, B.V. Sinn, C. Denkert, H. Oettle, H. Bläker, H. Riess, K. Jöhrens, J.K. Striefler, Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur. J. Cancer 83, 290–301 (2017)
208.
X. Liu, Z. Zhou, Q. Cheng, H. Wang, H. Cao, Q. Xu, Y. Tuo, L. Jiang, Y. Zou, H. Ren, M. Xiang, Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression. Cell Death Dis. 8, e3033 (2017)
209.
C. Lang, J. Wang, L. Chen, CD25-expressing Th17 cells mediate CD8+ T cell suppression in CTLA-4 dependent mechanisms in pancreatic ductal adenocarcinoma. Exp. Cell Res. 360, 384–389 (2017)
210.
R.B. Batchu, O.V. Gruzdyn, E.M. Mahmud, F. Chukr, R. Dachepalli, S.K. Manmari, G. Mostafa, D.W. Weaver, S.A. Gruber, Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. Surgery 163, 627–632 (2018)
211.
D.J. Gibson, L. Elliott, E. McDermott, M. Tosetto, D. Keegan, K. Byrne, S.T. Martin, T. Rispens, G. Cullen, H.E. Mulcahy, A.S. Cheifetz, A.C. Moss, S.C. Robson, G.A. Doherty, E.J. Ryan, Heightened expression of CD39 by regulatory T lymphocytes is associated with therapeutic remission in inflammatory bowel disease. Inflamm. Bowel Dis. 21, 2806–2814 (2015)
212.
M. Elshal, A. Aldahlawi, O. Saadah, J. McCoy, Reduced dendritic cells expressing CD200R1 in children with inflammatory bowel disease: Correlation with Th17 and regulatory T cells. Int. J. Mol. Sci. 16, 28998–29010 (2015)
213.
M. Mohammadnia-Afrouzi, A. Zavaran Hosseini, A. Khalili, S. Abediankenari, V. Hosseini, I. Maleki, Decrease of CD4 + CD25 + CD127 low FoxP3 + regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients. Autoimmunity 48, 556–561 (2015)
214.
M. Mohammadnia-Afrouzi, A.Z. Hosseini, A. Khalili, S. Abediankenari, A. Amari, B. Aghili, H.H. Nataj, Altered microRNA expression and immunosuppressive cytokine production by regulatory T cells of ulcerative colitis patients. Immunol. Invest. 45, 63–74 (2016)
215.
M. Föhlinger, P. Palamides, U. Mansmann, F. Beigel, M. Siebeck, R. Gropp, Immunological profiling of patients with ulcerative colitis leads to identification of two inflammatory conditions and CD1a as a disease marker. J. Transl. Med. 14, 310 (2016)
216.
Z. Liu, F. Kong, J.E. Vallance, E. Harmel-Laws, S. Amarachintha, K.A. Steinbrecher, M.J. Rosen, S. Bhattacharyya, Activation of TGF- β activated kinase 1 promotes colon mucosal pathogenesis in inflammatory bowel disease. Physiol. Rep. 5, e13181 (2017)
217.
Y. Liu, X. Sun, X. Zhao, L. An, Z. Wang, J. Jiang, W. Shen, X. Yang, Y. Sun, Expression and location of IL-17A. E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. Pathol. - Res. Pract. 214, 482–491 (2018)
218.
A. Steinert, I. Linas, B. Kaya, M. Ibrahim, A. Schlitzer, P. Hruz, K. Radulovic, L. Terracciano, A.J. Macpherson, J.H. Niess, The stimulation of macrophages with TLR ligands supports increased IL-19 expression in inflammatory bowel disease patients and in colitis models. J. Immunol. 199, 2570–2584 (2017)
219.
D. Waniczek, Z. Lorenc, M. Śnietura, M. Wesecki, A. Kopec, M. Muc-Wierzgoń, Tumor-associated mmacrophages and regulatory T cells infiltration and the clinical outcome in colorectal Cancer. Arch. Immunol. Ther. Exp. 65, 445–454 (2017)
220.
P. Akeus, L. Szeponik, F. Ahlmanner, P. Sundström, S. Alsén, B. Gustavsson, T. Sparwasser, S. Raghavan, M. Quiding-Järbrink, Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APCmin/+ mice. Cancer Immunol. Immunother. 67, 1067–1077 (2018)
221.
A.S. Syed Khaja, S.M. Toor, H. El Salhat, B.R. Ali, E. Elkord, Intratumoral FoxP3+Helios+ regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal cancer. Front Immunol. 8, 619 (2017)
222.
A.M. Westendorf, K. Skibbe, A. Adamczyk, J. Buer, R. Geffers, W. Hansen, E. Pastille, V. Jendrossek, Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting Treg activity. Cell Physiol. Biochem. 41, 1271–1284 (2017)
223.
J. Sugita, K. Fujiu, Systemic inflammatory stress response during cardiac surgery. Int. Heart J. 59, 457–459 (2018)
224.
A.S. Kimball, A.D. Joshi, A.E. Boniakowski, M. Schaller, J. Chung, R. Allen, J. Bermick, W.F. Carson, P.K. Henke, I. Maillard, S.L. Kunkel, K.A. Gallagher, Notch regulates macrophage-mediated inflammation in diabetic wound healing. Front Immunol. 8, 635 (2017)
225.
J. Zhang, X. Huang, B. Lu, C. Zhang, Z. Cai, Can apical periodontitis affect serum levels of CRP, IL-2, and IL-6 as well as induce pathological changes in remote organs? Clin. Oral. Investig. 20, 1617–1624 (2016)
226.
D. Zhang, J. Ren, M.O. Arafeh, R.G. Sawyer, Q. Hu, X. Wu, G. Wang, G. Gu, J. Hu, M. Li, The significance of interleukin-6 in the early detection of surgical site infections after definitive operation for gastrointestinal fistulae. Surg. Infect. 19, 523–528 (2018)
227.
J.D. Birkmeyer, J.F. Finks, A. O’Reilly, M. Oerline, A.M. Carlin, A.R. Nunn, J. Dimick, M. Banerjee, N.J.O. Birkmeyer, Surgical skill and complication rates after bariatric surgery. N. Engl. J. Med. 369, 1434–1442 (2013)
228.
N.R. Sproston, J.J. Ashworth, Role of c-reactive protein at sites of inflammation and infection. Front Immunol. 9, 754 (2018)
229.
K. Lepik, T. Annilo, V. Kukuškina, K. Kisand, Z. Kutalik, P. Peterson, H. Peterson, C-reactive protein upregulates the whole blood expression of CD59 - an integrative analysis. PLOS Comput. Biol. 13, e1005766 (2017)
230.
J. Cardone, S. Al-Shouli, C. Kemper, A novel role for CD46 in wound repair. Front Immunol. 2, 28 (2011)
231.
A.K. Piccoli, A.P. Alegretti, L. Schneider, P.S. Lora, R.M. Xavier, Expressão de proteínas reguladoras do complemento CD55, CD59, CD35 e CD46 na artrite reumatoide [Expression of complement regulatory proteins CD55, CD59, CD35, and CD46 in rheumatoid arthritis]. Rev. Bras. Reumatol. 51, 503–510 (2011)
232.
S.H. Li, P.E. Szmitko, R.D. Weisel, C.H. Wang, P.W.M. Fedak, R.K. Li, D.A.G. Mickle, S. Verma, C-reactive protein upregulates complement-inhibitory factors in endothelial eells. Circulation 109, 833–836 (2004)
233.
Y. Li, Y. Wang, L. Zhou, M. Liu, G. Liang, R. Yan, Y. Jiang, J. Hao, X. Zhang, X. Hu, Y. Huang, R. Wang, Z. Yin, J. Wu, G. Luo, W. He, Vγ4 T cells inhibit the pro-healing functions of dendritic epidermal T cells to delay skin wound closure through IL-17A. Front Immunol. 9, 240 (2018)
234.
H. Tanno, K. Kawakami, E. Kanno, A. Suzuki, N. Takagi, H. Yamamoto, K. Ishii, Y. Imai, R. Maruyama, M. Tachi, Invariant NKT cells promote skin wound healing by preventing a prolonged neutrophilic inflammatory response. Wound Repair Regen. 25, 805–815 (2017)
235.
M. Stanczyk, W.L. Olszewski, M. Gewartowska, M. Maruszynski, Lack of healing reaction in the cancer wound. Polish J. Pathol. 4, 267–275 (2014)
236.
F. Fazioli, G. Colella, R. Miceli, M.G. Di Salvatore, M. Gallo, S. Boccella, A. De Chiara, C. Ruosi, F. de Nigris, Post-surgery fluids promote transition of cancer stem cell- to-endothelial and AKT/mTOR activity, contributing to relapse of giant cell tumors of bone. Oncotarget 8, 85040–85053 (2017)
237.
A.J. Long, P.R. Burton, M.J. De Veer, G.J. Ooi, C.P. Laurie, P.D. Nottle, M.J. Watt, W.A. Brown, Radical gastric cancer surgery results in widespread upregulation of pro-tumourigenic intraperitoneal cytokines. ANZ J. Surg. 88, E370 (2018)
238.
I. Göcze, K. Ehehalt, F. Zeman, P. Riquelme, K. Pfister, B.M. Graf, T. Bein, E.K. Geissler, P. Kasprzak, H.J. Schlitt, J.A. Kellum, J.A. Hutchinson, E. Eggenhofer, P. Renner, Postoperative cellular stress in the kidney is associated with an early systemic γδ T-cell immune cell response. Crit. Care 22, 168 (2018)
239.
C. G. Park, C. A. Hartl, D. Schmid, E. M. Carmona, H. J. Kim, M. S. Goldberg, Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci. Transl. Med. 10, eaar1916 (2018)
240.
J.T. Rodrigues, H. dos Santos Antunes, L. Armada, F.R. Pires, Influence of surgical decompression on the expression of inflammatory and tissue repair biomarkers in periapical cysts. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. 124, 561–567 (2017)
241.
I. Segatto, S. Berton, M. Sonego, S. Massarut, T. Perin, E. Piccoli, A. Colombatti, A. Vecchione, G. Baldassarre, B. Belletti, Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, via STAT3 signaling. Oncotarget 5, 6267–6279 (2014)
242.
V.S. Lucas, N. McCain, R.K. Elswick, A.L. Pozez, Perceived stress and surgical wound cytokine patterns. Plast. Surg. Nurs. 38, 55–72 (2018)
243.
H. Koschwanez, M. Vurnek, J. Weinman, J. Tarlton, C. Whiting, S. Amirapu, S. Colgan, D. Long, P. Jarrett, E. Broadbent, Stress-related changes to immune cells in the skin prior to wounding may impair subsequent healing. Brain Behav. Immun. 50, 47–51 (2015)
244.
S.L. Doyle, A.M. Mongan, C.L. Donohoe, G.P. Pidgeon, M. Sherlock, J.V. Reynolds, J. Lysaght, Impact of visceral obesity and metabolic syndrome on the postoperative immune, inflammatory, and endocrine response following surgery for esophageal adenocarcinoma. Dis. Esophagus 30, 1–11 (2017)
245.
R.V. Jimenez, T.T. Wright, N.R. Jones, J. Wu, A.W. Gibson, A.J. Szalai, C-reactive protein impairs dendritic cell development, maturation, and function: Implications for peripheral tolerance. Front Immunol. 9, 372 (2018)
246.
E.P. van der Stok, D.J. Grunhagen, J. Rothbarth, C. Verhoef, The prognostic value of post-operative serum C-reactive protein level for survival after surgery for colorectal liver metastases. Acta. Chir. Belg. 115, 348–355 (2015)
247.
J. You, X. Shi, H. Liang, J. Ye, L. Wang, H. Han, H. Fang, W. Kang, T. Wang, Cystathionine-gamma-lyase promotes process of breast cancer in association with STAT3 signaling pathway. Oncotarget 8, 65677–65686 (2017)
248.
L.S. Ojalvo, E.D. Thompson, T.L. Wang, A.K. Meeker, I.M. Shih, A.N. Fader, A. Cimino-Mathews, L.A. Emens, Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. Hum. Pathol. 74, 135–147 (2018)
249.
M. Stanske, S. Wienert, D.C. Castillo-Tong, C. Kreuzinger, I. Vergote, S. Lambrechts, H. Gabra, C. Gourley, R.N. Ganapathi, I. Kolaschinski, J. Budczies, J. Sehouli, I. Ruscito, C. Denkert, H. Kulbe, W. Schmitt, K. Jöhrens, I. Braicu, S. Darb-Esfahani, Dynamics of the intratumoral immune response during progression of high-grade serous ovarian cancer. Neoplasia 20, 280–288 (2018)
250.
W. Zhang, Z. Zhou, M. Guo, L. Yang, Y. Xu, T. Pang, S. Gao, X. Xu, Q. Sun, M. Feng, H. Wang, C. Lu, G. Wu, W. Guan, G. Xu, High infiltration of polarized CD163 + tumor-associated macrophages correlates with aberrant expressions of CSCs markers, and predicts prognosis in patients with recurrent gastric cancer. J. Cancer 8, 363–370 (2017)
251.
M. Rahman, J. Kresak, C. Yang, J. Huang, W. Hiser, P. Kubilis, D. Mitchell, Analysis of immunobiologic markers in primary and recurrent glioblastoma. J. Neurooncol. 137, 249–257 (2018)
252.
M. Mohme, S. Schliffke, C.L. Maire, A. Rünger, L. Glau, K.C. Mende, J. Matschke, C. Gehbauer, N. Akyüz, S. Zapf, M. Holz, M. Schaper, T. Martens, N.O. Schmidt, S. Peine, M. Westphal, M. Binder, E. Tolosa, K. Lamszus, Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin. Cancer Res. 24, 4187–4200 (2018)
253.
S. Heynckes, A. Gaebelein, G. Haaker, J. Grauvogel, P. Franco, I. Mader, M.S. Carro, M. Prinz, D. Delev, O. Schnell, D.H. Heiland, Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. Oncotarget 8, 74170–74177 (2017)
254.
G. Sánchez-Pedrosa, E. Vara Ameigeiras, J. Casanova Barea, L. Rancan, C.M. Simón Adiego, I. Garutti Martínez, Role of surgical manipulation in lung inflammatory response in a model of lung resection surgery. Interact Cardiovasc. Thorac. Surg. 27, 870–877 (2018)
255.
S.K. Watt, H.C. Hasselbalch, V. Skov, L. Kjær, M. Thomassen, T.A. Kruse, M. Burton, I. Gögenur, Whole Blood Gene Expression Profiling in patients undergoing colon cancer surgery identifies differential expression of genes involved in immune surveillance, inflammation and carcinogenesis. Surg. Oncol. 27, 208–215 (2018)
256.
M. Wu, X. Chen, J. Lou, S. Zhang, X. Zhang, L. Huang, R. Sun, P. Huang, S. Pan, F. Wang, Changes in regulatory T cells in patients with ovarian cancer undergoing surgery: Preliminary results. Int. Immunopharmacol. 47, 244–250 (2017)
257.
A. Arimoto, K. Yamashita, H. Hasegawa, Y. Sugita, E. Fukuoka, T. Tanaka, S. Suzuki, Y. Kakeji, Immunosuppression induced by perioperative peritonitis promotes lung metastasis. Anticancer Res. 38, 4333–4338 (2018)
258.
A. Schietinger, M. Philip, V.E. Krisnawan, E.Y. Chiu, J.J. Delrow, R.S. Basom, P. Lauer, D.G. Brockstedt, S.E. Knoblaugh, G.J. Hämmerling, T.D. Schell, N. Garbi, P.D. Greenberg, Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389–401 (2016)
259.
S. Shiono, J. Yoshida, M. Nishimura, M. Hagiwara, T. Hishida, J. Nitadori, K. Nagai, Risk factors of postoperative respiratory infections in lung cancer surgery. J. Thorac. Oncol. 2, 34–38 (2007)
260.
A.T. Malik, N. Jain, T.J. Scharschmidt, J.L. Mayerson, S.N. Khan, Factors associated with post-operative sepsis following surgery for spinal tumors: An analysis of the ACS-NSQIP database. Clin. Neurol. Neurosurg. 172, 1–7 (2018)
261.
S.H. Chen, W.J. Chen, M.H. Wu, J.C. Liao, C.J. Fu, Postoperative infection in patients undergoing posterior lumbosacral spinal surgery. Clin. Spine Surg. 31, 225–238 (2018)
262.
J.F. Velásquez, M.F. Ramírez, D.I. Ai, V. Lewis, J.P. Cata, Impaired immune function in patients undergoing surgery for bone cancer. Anticancer Res. 35, 5461–5466 (2015)
263.
Y. Wang, X. Qu, N.W. Kam, K. Wang, H. Shen, Q. Liu, J. Du, An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy. BMC Cancer 18, 692 (2018)
264.
H.Y. Min, H.Y. Lee, Oncogene-driven metabolic alterations in cancer. Biomol. Ther. (Seoul) 26, 45–56 (2018)
265.
C. Blücher, C. Zilberfain, T. Venus, N. Spindler, A. Dietrich, R. Burkhardt, S.C. Stadler, I. Estrela-Lopis, Single cell study of adipose tissue mediated lipid droplet formation and biochemical alterations in breast cancer cells. Analyst 144, 5558–5570 (2019)
266.
M. Haffa, A.N. Holowatyj, M. Kratz, R. Toth, A. Benner, B. Gigic, N. Habermann, P. Schrotz-King, J. Böhm, H. Brenner, M. Schneider, A. Ulrich, E. Herpel, P. Schirmacher, B.K. Straub, J. Nattenmüller, H.U. Kauczor, T. Lin, C.R. Ball, C.M. Ulrich, H. Glimm, D. Scherer, Transcriptome profiling of adipose tissue reveals depot-specific metabolic alterations among patients with colorectal cancer. J. Clin. Endocrinol. Metab. 104, 5225–5237 (2019)
267.
C. Himbert, J. Ose, J. Nattenmüller, C.A. Warby, A.N. Holowatyj, J. Böhm, T. Lin, M. Haffa, B. Gigic, S. Hardikar, D. Scherer, L. Zielske, P. Schrotz-King, T. Kölsch, E.M. Siegel, D. Shibata, A. Ulrich, M. Schneider, S.D. Hursting, H.U. Kauczor, C.M. Ulrich, Body fatness, adipose tissue compartments, and biomarkers of inflammation and angiogenesis in colorectal cancer: The ColoCare Study. Cancer Epidemiol. Biomarkers Prev. 28, 76–82 (2019)
268.
G. Ascolani, P. Liò, Modeling breast cancer progression to bone: how driver mutation order and metabolism matter. BMC Med. Genomics 12, 106 (2019)
269.
E. Perucha, R. Melchiotti, J.A. Bibby, W. Wu, K.S. Frederiksen, C.A. Roberts, Z. Hall, G. LeFriec, K.A. Robertson, P. Lavender, J.G. Gerwien, L.S. Taams, J.L. Griffin, E. de Rinaldis, L.G.M. van Baarsen, C. Kemper, P. Ghazal, A.P. Cope, The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nat. Commun. 10, 498 (2019)
270.
M. Gjorgjieva, J. Calderaro, L. Monteillet, M. Silva, M. Raffin, M. Brevet, C. Romestaing, D. Roussel, J. Zucman-Rossi, G. Mithieux, F. Rajas, Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. J. Hepatol. 69, 1074–1087 (2018)
271.
N. Fliss-Isakov, S. Zelber-Sagi, M. Webb, Z. Halpern, O. Shibolet, R. Kariv, Distinct metabolic profiles are associated with colorectal adenomas and serrated polyps. Obesity 25, S72–S80 (2017)
272.
I. Roci, J.D. Watrous, K.A. Lagerborg, L. Lafranchi, A. Lindqvist, M. Jain, R. Nilsson, Mapping metabolic events in the cancer cell cycle reveals arginine catabolism in the committed SG2M phase. Cell Rep. 26, 1691–1700 (2019)
273.
N. Avtandilyan, H. Javrushyan, G. Petrosyan, A. Trchounian, The involvement of arginase and nitric oxide synthase in breast cancer development: Arginase and NO synthase as therapeutic targets in cancer. Biomed. Res. Int. 2018, 1–9 (2018)
274.
W. Peng, W. Huang, X. Ge, L. Xue, W. Zhao, J. Xue, Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. EBioMedicine 44, 375–386 (2019)
275.
A. Stadtmann, H. Block, S. Volmering, C. Abram, C. Sohlbach, M. Boras, C.A. Lowell, A. Zarbock, Cross-talk between Shp1 and PIPKIγ controls leukocyte recruitment. J. Immunol. 195, 1152–1161 (2015)
276.
J. Xue, C. Chen, M. Qi, Y. Huang, L. Wang, Y. Gao, H. Dong, K. Ling, Type I gamma-phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κβ. Oncotarget 8, 42414–42427 (2017)
277.
Y. Deng, J. Yang, F. Luo, J. Qian, R. Liu, D. Zhang, H. Yu, Y. Chu, mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells. Cancer Immunol. Immunother. 67, 1355–1364 (2018)
278.
X. Qian, Q. Zhang, N. Shao, Z. Shan, T. Cheang, Z. Zhang, Q. Su, S. Wang, Y. Lin, Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model. Am. J. Cancer Res. 9, 529–545 (2019)
279.
T. Bohn, S. Rapp, N. Luther, M. Klein, T.J. Bruehl, N. Kojima, P. Aranda Lopez, J. Hahlbrock, S. Muth, S. Endo, S. Pektor, A. Brand, K. Renner, V. Popp, K. Gerlach, D. Vogel, C. Lueckel, D. Arnold-Schild, J. Pouyssegur, M. Kreutz, M. Huber, J. Koenig, B. Weigmann, H.C. Probst, E. von Stebut, C. Becker, H. Schild, E. Schmitt, T. Bopp, Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat. Immunol. 19, 1319–1329 (2018)
280.
L. Li, H. Yang, Y. Li, X.D. Li, T.T. Zeng, S.X. Lin, Y.H. Zhu, X.Y. Guan, Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression. Cell Death Discov. 4, 63 (2018)
281.
X.J. Chen, S. Wu, R.M. Yan, L.S. Fan, L. Yu, Y.M. Zhang, W.F. Wei, C.F. Zhou, X.G. Wu, M. Zhong, Y.H. Yu, L. Liang, W. Wang, The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer. Mol. Carcinog. 58, 388–397 (2019)
282.
H. Jeong, S. Kim, B.J. Hong, C.J. Lee, Y.E. Kim, S. Bok, J.M. Oh, S.H. Gwak, M.Y. Yoo, M.S. Lee, S.J. Chung, J. Defrêne, P. Tessier, M. Pelletier, H. Jeon, T.Y. Roh, B. Kim, K.H. Kim, J.H. Ju, S. Kim, Y.J. Lee, D.W. Kim, I.H. Kim, H.J. Kim, J.W. Park, Y.S. Lee, J.S. Lee, G.J. Cheon, I.L. Weissman, D.H. Chung, Y.K. Jeon, G.O. Ahn, Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis. Cancer Res. 79, 795–806 (2019)
283.
X. Ma, E. Bi, C. Huang, Y. Lu, G. Xue, X. Guo, A. Wang, M. Yang, J. Qian, C. Dong, Q. Yi, Cholesterol negatively regulates IL-9–producing CD8+ T cell differentiation and antitumor activity. J. Exp. Med. 215, 1555–1569 (2018)
284.
X. Li, Z. Liu, Y. Wu, H. Wu, W. Dai, B. Arshad, Z. Xu, H. Li, K. Wu, L. Kong, Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis. 17, 91 (2018)
285.
Y. Wang, Z. Wang, F. Wang, X. Lei, S. Yan, D. Wang, F. Zhang, R. Xu, L. Wang, Y. Li, Predictive value of chemotherapy-related high-density lipoprotein cholesterol (HDL) elevation in patients with colorectal cancer receiving adjuvant chemotherapy: an exploratory analysis of 851 cases. Oncotarget 7, 57290–57300 (2016)
286.
F. Liao, W. He, C. Jiang, C. Yin, G. Guo, X. Chen, H. Qiu, Y. Rong, B. Zhang, D. Xu, L. Xia, A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C. Onco. Targets Ther. 8, 3135–3142 (2015)
287.
I. Benghalem, W. Meziane, Z. Hadjidj, L. Ysmail-Dahlouk, A. Belamri, K. Mouhadjer, M. Aribi, High-density lipoprotein immunomodulates the functional activities of macrophage and cytokines produced during ex vivo macrophage-CD4 + T cell crosstalk at the recent-onset human type 1 diabetes. Cytokine 96, 59–70 (2017)
288.
A.G. Moraitis, L.A. Freeman, R.D. Shamburek, R. Wesley, W. Wilson, C.M. Grant, S. Price, S. Demosky, S.G. Thacker, A. Zarzour, R.L. Hornung, F. Pucino, G. Csako, C. Yarboro, I.B. McInnes, T. Kuroiwa, D. Boumpas, V.K. Rao, G.G. Illei, A.T. Remaley, Elevated interleukin-10: A new cause of dyslipidemia leading to severe HDL deficiency. J. Clin. Lipidol. 9, 81–90 (2015)
289.
Y. Wang, S. Lu, G. Zhang, S. Wu, Y. Yan, Q. Dong, B. Liu, Anti-inflammatory effects of HDL in mice with rheumatoid arthritis induced by collagen. Front Immunol. 9, 1013 (2018)
290.
K. Muhammad, H. Alrefai, R. Marienfeld, D.A.T. Pham, K. Murti, A.K. Patra, A. Avots, V. Bukur, U. Sahin, E. Kondo, S. Klein-Hessling, E. Serfling, NF-κB factors control the induction of NFATc1 in B lymphocytes. Eur. J. Immunol. 44, 3392–3402 (2014)
291.
T. Maj, W. Wang, J. Crespo, H. Zhang, W. Wang, S. Wei, L. Zhao, L. Vatan, I. Shao, W. Szeliga, C. Lyssiotis, J.R. Liu, I. Kryczek, W. Zou, Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332–1341 (2017)
292.
J. Kjaergaard, S. Hatfield, G. Jones, A. Ohta, M. Sitkovsky, A 2A adenosine receptor gene deletion or synthetic A 2A antagonist liberate tumor-reactive CD8 + T cells from tumor-induced immunosuppression. J. Immunol. 201, 782–791 (2018)
293.
S. Baharaghdam, M. Yousefi, A. Movasaghpour, S. Solali, M. Talebi, M. Ahani-Nahayati, H. Lotfimehr, K. Shamsasanjan, Effects of hypoxia on biology of human leukemia T-cell line (MOLT-4 cells) co-cultured with bone marrow mesenchymal stem cells. Avicenna J. Med. Biotechnol. 10, 62–68 (2018)
294.
B. Kindlund, Å. Sjöling, C. Yakkala, J. Adamsson, A. Janzon, L.E. Hansson, M. Hermansson, P. Janson, O. Winqvist, S.B. Lundin, CD4+ regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-β. Gastric Cancer 20, 116–125 (2017)
295.
A. Bieńkowska, E. Kiernozek, E. Kozlowska, Ł. Bugajski, N. Drela, A new approach to the role of IL-7 and TGF-ß in the in vitro generation of thymus-derived CD4+CD25+Foxp3+ regulatory T cells. Cytokine 102, 107–116 (2018)
296.
E. Shakiba, M. Ramezani, M. Sadeghi, Evaluation of serum interleukin-10 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin. Exp. Hepatol. 4, 35–40 (2018)
297.
M. Krzystek-Korpacka, M. Zawadzki, B. Kapturkiewicz, P. Lewandowska, I. Bednarz-Misa, S. Gorska, W. Witkiewicz, A. Gamian, Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer. Cytokine 110, 435–441 (2018)
298.
I. Sghaier, L. Mouelhi, N.A. Rabia, B.R. Alsaleh, E. Ghazoueni, W.Y. Almawi, B.Y. Loueslati, Genetic variants in IL-6 and IL-10 genes and susceptibility to hepatocellular carcinoma in HCV infected patients. Cytokine 89, 62–67 (2017)
299.
R.L. Lopes, T.J. Borges, R.F. Zanin, C. Bonorino, IL-10 is required for polarization of macrophages to M2-like phenotype by mycobacterial DnaK (heat shock protein 70). Cytokine 85, 123–129 (2016)
300.
S. An, D. Zenisek, Regulation of exocytosis in neurons and neuroendocrine cells. Curr. Opin. Neurobiol. 14, 522–530 (2004)
301.
V.R. Minciacchi, M.R. Freeman, D. Di Vizio, Extracellular vesicles in cancer: Exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev. Biol. 40, 41–51 (2015)
302.
A.S. Azmi, B. Bao, F.H. Sarkar, Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 32, 623–642 (2013)
303.
E. Machado, S. White-Gilbertson, D. van de Vlekkert, L. Janke, S. Moshiach, Y. Campos, D. Finkelstein, E. Gomero, R. Mosca, X. Qiu, C.L. Morton, I. Annunziata, A. D’Azzo, Regulated lysosomal exocytosis mediates cancer progression. Sci. Adv. 1, e1500603 (2015)
304.
H. Zhang, D. Lyden, Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. Nat. Protoc. 14, 1027–1053 (2019)
305.
Q. Zhang, J.N. Higginbotham, D.K. Jeppesen, Y.P. Yang, W. Li, E.T. McKinley, R. Graves-Deal, J. Ping, C.M. Britain, K.A. Dorsett, C.L. Hartman, D.A. Ford, R.M. Allen, K.C. Vickers, Q. Liu, J.L. Franklin, S.L. Bellis, R.J. Coffey, Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 (2019)
306.
H. Zhang, D. Freitas, H. S. Kim, K. Fabijanic, Z. Li, H. Chen, M. T. Mark, H. Molina, A. B. Martin, L. Bojmar, J. Fang, S. Rampersaud, A. Hoshino, I. Matei, C. M. Kenific, M. Nakajima, A. P. Mutvei, P. Sansone, W. Buehring, H. Wang, J. P. Jimenez, L. Cohen-Gould, N. Paknejad, M. Brendel, K. Manova-Todorova, A. Magalhães, J. A. Ferreira, H. Osório, A. M. Silva, A. Massey, J. R. Cubillos-Ruiz, G. Galletti, P. Giannakakou, A. M. Cuervo, J. Blenis, R. Schwartz, M. S. Brady, H. Peinado, J. Bromberg, H. Matsui, C. A. Reis, D. Lyden, Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)
307.
E. van der Pol, F.A.W. Coumans, A.E. Grootemaat, C. Gardiner, I.L. Sargent, P. Harrison, A. Sturk, T.G. van Leeuwen, R. Nieuwland, Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J. Thromb. Haemost. 12, 1182–1192 (2014)
308.
R. Kalluri, The biology and function of exosomes in cancer. J. Clin. Invest. 126, 1208–1215 (2016)
309.
C. Théry, L. Zitvogel, S. Amigorena, Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569–579 (2002)
310.
G. Raposo, H.W. Nijman, W. Stoorvogel, R. Liejendekker, C.V. Harding, C.J. Melief, H.J. Geuze, B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 183(1161–1172) (1996)
311.
I.S. Okoye, S.M. Coomes, V.S. Pelly, S. Czieso, V. Papayannopoulos, T. Tolmachova, M.C. Seabra, M.S. Wilson, MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 41, 503 (2014)
312.
W. Ren, X. Zhang, W. Li, Q. Feng, H. Feng, Y. Tong, H. Rong, W. Wang, D. Zhang, Z. Zhang, S. Tu, X. Zhu, Q. Zhang, Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag. Res. 11, 4023–4040 (2019)
313.
L. Li, B. Cao, X. Liang, S. Lu, H. Luo, Z. Wang, S. Wang, J. Jiang, J. Lang, G. Zhu, Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes. Oncogene 38, 2830–2843 (2019)
314.
L. Geis-Asteggiante, A.T. Belew, V.K. Clements, N.J. Edwards, S. Ostrand-Rosenberg, N.M. El-Sayed, C. Fenselau, Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. J. Proteome. Res. 17, 486–498 (2018)
315.
Y. Wang, J. Tian, X. Tang, K. Rui, X. Tian, J. Ma, B. Ma, H. Xu, L. Lu, S. Wang, Exosomes released by granulocytic myeloid-derived suppressor cells attenuate DSS-induced colitis in mice. Oncotarget 7, 15356–15368 (2016)
316.
R. Domenis, D. Cesselli, B. Toffoletto, E. Bourkoula, F. Caponnetto, I. Manini, A.P. Beltrami, T. Ius, M. Skrap, C. Di Loreto, G. Gri, Systemic T cells immunosuppression of glioma stem cell-derived exosomes is mediated by monocytic myeloid-derived suppressor cells. PLoS One 12, e0169932 (2017)
317.
D. Zhu, J. Tian, X. Wu, M. Li, X. Tang, K. Rui, H. Guo, J. Ma, H. Xu, S. Wang, G-MDSC-derived exosomes attenuate collagen-induced arthritis by impairing Th1 and Th17 cell responses. Biochim. Biophys. Acta. - Mol. Basis Dis. 1865, 165540 (2019)
318.
K. Al-Nedawi, B. Meehan, J. Micallef, V. Lhotak, L. May, A. Guha, J. Rak, Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)
319.
V.R. Minciacchi, S. You, C. Spinelli, S. Morley, M. Zandian, P.J. Aspuria, L. Cavallini, C. Ciardiello, M.R. Sobreiro, M. Morello, G. Kharmate, S.C. Jang, D.K. Kim, E. Hosseini-Beheshti, E.T. Guns, M. Gleave, Y.S. Gho, S. Mathivanan, W. Yang, M.R. Freeman, D. Di Vizio, Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. Oncotarget 6, 11327–11341 (2015)
320.
T. H. Lee, E. D’Asti, N. Magnus, K. Al-Nedawi, B. Meehan, J. Rak, Microvesicles as mediators of intercellular communication in cancer—the emerging science of cellular ‘debris.’ Semin Immunopathol. 33, 455–467 (2011)
321.
F. Bordeleau, B. Chan, M.A. Antonyak, M.C. Lampi, R.A. Cerione, C.A. Reinhart-King, Microvesicles released from tumor cells disrupt epithelial cell morphology and contractility. J. Biomech. 49, 1272–1279 (2016)
322.
G. Berchem, M. Z. Noman, M. Bosseler, J. Paggetti, S. Baconnais, E. Le Cam, A. Nanbakhsh, E. Moussay, F. Mami-Chouaib, B. Janji, S. Chouaib, Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer. Oncoimmunology 5, e1062968 (2016)
323.
M. Baj-Krzyworzeka, B. Mytar, R. Szatanek, M. Surmiak, K. Węglarczyk, J. Baran, M. Siedlar, Colorectal cancer-derived microvesicles modulate differentiation of human monocytes to macrophages. J. Transl. Med. 14, 36 (2016)
324.
F. Gieseler, C. Plattfaut, T. Quecke, A. Freund, H. Ungefroren, F. Ender, Heterogeneity of microvesicles from cancer cell lines under inflammatory stimulation with TNF- α. Cell Biol. Int. 42, 1533–1544 (2018)
325.
J. Cui, Q. Li, M. Luo, Z. Zhong, S. Zhou, L. Jiang, N. Shen, Z. Geng, H. Cheng, L. Meng, S. Yi, H. Sun, F. Wu, Z. Zhu, P. Zou, Y. You, A.Y. Guo, X. Zhu, Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery. Oncoimmunology 7, e1448330 (2018)
326.
E.U. Wieckowski, C. Visus, M. Szajnik, M.J. Szczepanski, W.J. Storkus, T.L. Whiteside, Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J. Immunol. 183, 3720–3730 (2009)
327.
X. Zhang, X. Yuan, H. Shi, L. Wu, H. Qian, W. Xu, Exosomes in cancer: small particle, big player. J. Hematol. Oncol. 8, 83 (2015)
328.
J. Salimu, J. Webber, M. Gurney, S. Al-Taei, A. Clayton, Z. Tabi, Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes. J. Extracell Vesicles 6, 1368823 (2017)
329.
G.T. Szabó, B. Tarr, K. Pálóczi, K. Éder, E. Lajkó, Á. Kittel, S. Tóth, B. György, M. Pásztói, A. Németh, X. Osteikoetxea, É. Pállinger, A. Falus, K. Szabó-Taylor, E.I. Buzás, Critical role of extracellular vesicles in modulating the cellular effects of cytokines. Cell Mol. Life Sci. 71, 4055–4067 (2014)
330.
E. Martínez-Martínez, A. Martín-Ruíz, P. Martín, V. Calvo, M. Provencio, J.M. García, CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3β signaling pathway. Oncotarget 7, 68781–68791 (2016)
331.
L. Cheng, J. Liu, Q. Liu, Y. Liu, L. Fan, F. Wang, H. Yu, Y. Li, L. Bu, X. Li, W. Wei, H. Wang, G. Sun, Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages. Int. J. Biol. Sci. 13, 723–734 (2017)
332.
J. Qiu, G. Yang, M. Feng, S. Zheng, Z. Cao, L. You, L. Zheng, T. Zhang, Y. Zhao, Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Mol. Cancer 17, 2 (2018)
333.
N. Dioufa, A.M. Clark, B. Ma, C.H. Beckwitt, A. Wells, Bi-directional exosome-driven intercommunication between the hepatic niche and cancer cells. Mol. Cancer 16, 172 (2017)
334.
J. Rak, Organ-seeking vesicles. Nature 527, 312–314 (2015)
335.
A. N. Kremer, M. I. Zonneveld, A. E. Kremer, E. D. van der Meijden, J. H. F. Falkenburg, M. H. M. Wauben, E.N.M. Nolte-‘t Hoen, M. Griffioen, Natural T-cell ligands that are created by genetic variants can be transferred between cells by extracellular vesicles. Eur. J. Immunol. 48, 1621–1631 (2018)
Metadata
Title
Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance
Authors
Łukasz Zadka
Damian J. Grybowski
Piotr Dzięgiel
Publication date
01-08-2020
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00519-3

Other articles of this Issue 4/2020

Cellular Oncology 4/2020 Go to the issue

Original paper

PFKP is highly expressed in lung cancer and regulates glucose metabolism

Report

Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression

Original paper

IL-17A and IL-17F orchestrate macrophages to promote lung cancer

Original paper

Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications

Original paper

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis

Original paper

Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits